Tinodasertib
Term · Oncology and biomedicine · MLC-T-ONC-017176
A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, tinodasertib may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.
| Identifier | MLC-T-ONC-017176 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | MNK1/2 inhibitor ETC-1907206 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017176",
"term": "Tinodasertib",
"field": "Oncology and biomedicine",
"definition": "A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, tinodasertib may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.",
"synonyms": [
"MNK1/2 inhibitor ETC-1907206"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/tinodasertib/"
}
Record 16,378 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.